Moderna Stock Price, News & Analysis

Moderna Inc. (Nasdaq: MRNA) has initiated a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, mRNA-1273, targeting adolescents aged 12 to less than 18. This study, supported by BARDA, aims to enroll 3,000 participants in the U.S. and evaluate safety, reactogenicity, and immunogenicity with two vaccinations 28 days apart. Results are expected in spring 2021 to inform potential use ahead of the school year. The vaccine, co-developed with NIAID, is not yet approved for use.

Moderna (Nasdaq: MRNA) announced a significant increase in its confirmed order from the Canadian government for its COVID-19 vaccine candidate, mRNA-1273. The order has grown by 20 million doses, totaling 40 million doses. Moderna is progressing towards potential delivery as early as December, pending regulatory approval. The efficacy analysis from the Phase 3 COVE study reported a 94.1% vaccine efficacy, with safety monitoring ongoing. The vaccine supply will be sourced from Moderna's European production capabilities, emphasizing its collaboration with various international partners.

Moderna, Inc. (Nasdaq: MRNA) announced an expanded supply agreement with the Israeli Ministry of Health for an additional 4 million doses of its COVID-19 vaccine candidate, mRNA-1273, totaling 6 million doses. This agreement aims to provide early access to the vaccine for Israeli citizens. Moderna has initiated the regulatory review process with Israel's Ministry of Health. The primary efficacy analysis of the Phase 3 COVE Study confirmed a vaccine efficacy of 94.1%, with the company ramping up global manufacturing capabilities to produce up to 1 billion doses annually.

Moderna, Inc. (Nasdaq: MRNA) provided an update on its COVID-19 vaccine candidate, mRNA-1273. Interim data from a NIH-led Phase 1 study showed that participants maintained high levels of neutralizing antibodies for up to 119 days post-first vaccination. The company anticipates producing 20 million doses by the end of 2020 and between 100 million and 125 million doses globally in Q1 2021. mRNA-1273 demonstrated a 94.1% efficacy rate in the Phase 3 study. No serious adverse events were noted, supporting the vaccine's safety profile.

Moderna, Inc. (MRNA) reports positive results from the Phase 3 COVE study of its mRNA-1273 COVID-19 vaccine, demonstrating an efficacy of 94.1%. The analysis included 196 cases, with 185 in the placebo group and 11 in the vaccine group, indicating strong performance across various demographics. Moderna plans to apply for Emergency Use Authorization (EUA) from the FDA and conditional approval from the EMA. The vaccine aims to prevent both symptomatic and severe COVID-19 disease, with expectations to manufacture 500 million to 1 billion doses globally in 2021.

Moderna, Inc. (Nasdaq: MRNA) has secured a supply agreement with the UK government for an additional 2 million doses of its COVID-19 vaccine candidate, mRNA-1273, starting March 2021. This brings the total doses committed to the UK to 7 million. The agreement supports the UK's strategy to ensure access to effective vaccines. Moderna has also reported a 94.5% efficacy rate from its Phase 3 clinical trials involving over 30,000 participants and plans to increase its production capacity to deliver up to 1 billion doses annually.

Moderna, Inc. (Nasdaq: MRNA) has announced its participation in several upcoming virtual investor conferences. Key events include the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, Nasdaq 43rd Virtual Investor Conference on December 4, 2020, and BMO 2020 Growth & ESG Conference on December 9, 2020. A live webcast of each presentation will be accessible on Moderna's investor website, with replays available for 30 days post-event.

Moderna, Inc. (Nasdaq: MRNA) has secured approval from the European Commission for an agreement to supply 80 million doses of its COVID-19 vaccine candidate, mRNA-1273. The contract, which can be expanded to 160 million doses, marks a significant step in the EU's efforts to secure access to effective vaccines. Pending regulatory approvals, deliveries may commence as early as Q1 2021. Moderna's vaccine has shown a promising efficacy rate of 94.5% in Phase 3 trials. The company is on track to manufacture up to 1 billion doses globally in 2021.

Moderna, a biotechnology company based in Cambridge, announced that the European Medicines Agency (EMA) has initiated a rolling review of its COVID-19 vaccine candidate, mRNA-1273. This follows the confirmation of eligibility for submission on October 14, 2020. The Phase 3 study of mRNA-1273 has reported an efficacy of 94.5%, involving over 30,000 participants. Moderna aims to scale up production to deliver 500 million doses annually, potentially reaching 1 billion doses by 2021, in collaboration with strategic partners Lonza and ROVI.